The European Commission has approved STADA and Alvotech's biosimilar Uzpruvo® (AVT04), similar to Stelara® (ustekinumab), for marketing.

Verge Genomics has announced the start of its Phase 1b trial for VRG50635, a potential treatment for amyotrophic lateral sclerosis (ALS), covering both sporadic and familial forms.

Corbus Pharmaceuticals Holdings, Inc., focused on precision oncology, announced FDA approval for its CRB-601 drug application.

Constant Therapeutics LLC, specializing in biopharmaceuticals, announced the first patient dosed in their Phase 2 trial of TXA127, a peptide therapy aimed at improving post-stroke recovery.

Pfizer and Genmab announced the FDA has accepted their supplemental application for TIVDAK.

Fate Therapeutics Reveals Commencement of Initial Human Trial for FT825 / ONO-8250 in Individuals Suffering from HER2-positive Progressive Solid Cancers.

Astellas Pharma Inc. announced on Jan 4, 2024, the FDA issued a complete response to their zolbetuximab Biologics License Application.

Medison Pharma and Regeneron Ireland DAC have formed an exclusive partnership for Medison to distribute Regeneron's innovative treatment, Libtayo® (cemiplimab).

Lutikizumab Demonstrates Encouraging Outcomes in Phase 2 Study Among Individuals with Moderate to Advanced Hidradenitis Suppurativa, Progressing to Next Trial Stage.

Innovent declared the successful completion of the initial stage 3 clinical evaluation for Mazdutide among overweight and obese adults in China.

The EU Commission has approved Eylea™ 8 mg, an 8 mg aflibercept (114.3 mg/ml) injectable, for treating neovascular age-related macular degeneration and diabetic macular edema-related vision loss.

Bayer announced positive early results from Phase III OASIS 1 and 2 trials, where the experimental drug elinzanetant outperformed placebo.